Document is current
Any future updates will be listed below
-
Authors
De Meyer, Steffi
Schaeverbeke, Jolien M.
Verberk, Inge M. W.
Gille, Benjamin
De Schaepdryver, Maxim
Luckett, Emma S.
Gabel, Silvy
Bruffaerts, Rose
Mauroo, Kimberley
Thijssen, Elisabeth H.
Stoops, Erik
Vanderstichele, Hugo M.
Teunissen, Charlotte E.
Vandenberghe, Rik
Poesen, Koen
-
Funding
Funding for this research was provided by:
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (135043)
VLAIO (120835)
Stichting Alzheimer Onderzoek (13007, 20170032)
Flanders Research Foundation (12Y1620N, 12I2121N, 11E6319N)
- License Information
-
More Information
Article History
Received: 10 September 2020
Accepted: 17 November 2020
First Online: 5 December 2020
Ethics approval and consent to participate
: The Ethics Committee of University Hospitals Leuven approved all study procedures (UZ Leuven reference numbers S51125 and S55892), and written informed consent was obtained from all participants.
: Not applicable
: S. De Meyer, J. Schaeverbeke, K. Poesen, B. Gille, M. De Schaepdryver, E. Luckett, S. Gabel and R. Bruffaerts declare that they have no competing interests.I. Verberk, E. Thijssen and C. Teunissen developed the SIMOA Amyblood assays in cooperation with ADx NeuroSciences.K. Mauroo is a full-time paid employee of ADx NeuroSciences.E. Stoops is a full-time paid employee and shareholder of ADx NeuroSciences.H. Vanderstichele is a co-founder of ADx NeuroSciences and a founder of Biomarkable.R. Vandenberghe was the PI of the phase 1 and 2 clinical trials with [<sup>18</sup>F]flutemetamol, and his institution has clinical trial agreements (with RV as PI) with Novartis, Roche and AbbVie.
